Biocon's Nine-Month Revenues Driven by Growth in Branded Formulations ... Business Wire India (press release) Q3FY11 on the back of strong Tacrolimus and MMF sales. Statins have remained buoyant with improved margin realization. Biocon's Fidaxomicin commercialization partner, Optimer, has received marketing approval for DIFICLIR™ tablets in the European Union ... |
